Can a radioated molecule shrink untreatable neuroblastoma?
NCT ID NCT01370330
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This trial offers a radioactive drug called 131I-MIBG to children and adults with advanced neuroblastoma that has not responded to standard treatments. The drug is designed to seek out and deliver radiation directly to tumor cells. The goal is to provide palliative control of the disease in a compassionate-use setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a radioactive drug called 131I-MIBG (metaiodobenzylguanidine) that delivers radiation directly to tumor cells
- What this could lead to
- If it works, this could offer a palliative treatment option for people with advanced neuroblastoma who have no standard therapies left.
- What could go wrong
- This is a small, compassionate-use protocol, not a controlled trial, so results may be limited. The treatment involves significant radiation exposure and requires stem cell backup for higher doses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
AVAILABLESan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to shrink rare adrenal tumors
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
- Targeted radiation zaps childhood brain tumors in early trial
- Could a smartphone replace clinic visits for rare tumor survivors?
- Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
- Triple-Attack CAR-T cells take aim at stubborn neuroblastoma